000309603 001__ 309603
000309603 005__ 20260202160244.0
000309603 0247_ $$2doi$$a10.1093/neuonc/noag016
000309603 0247_ $$2pmid$$apmid:41619789
000309603 0247_ $$2ISSN$$a1522-8517
000309603 0247_ $$2ISSN$$a1523-5866
000309603 037__ $$aDKFZ-2026-00253
000309603 041__ $$aEnglish
000309603 082__ $$a610
000309603 1001_ $$0P:(DE-HGF)0$$aGhasemi, David R$$b0$$eFirst author
000309603 245__ $$aA brief history of ependymoma.
000309603 260__ $$aOxford$$bOxford Univ. Press$$c2026
000309603 3367_ $$2DRIVER$$aarticle
000309603 3367_ $$2DataCite$$aOutput Types/Journal article
000309603 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770044469_1634685
000309603 3367_ $$2BibTeX$$aARTICLE
000309603 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309603 3367_ $$00$$2EndNote$$aJournal Article
000309603 500__ $$a#EA:B062#LA:B062# / #DKTKZFB26# / #NCTZFB26# / epub
000309603 520__ $$aEpendymoma represents a biologically and clinically heterogeneous group of glial tumours that arise throughout the whole neuroaxis and in all age groups. Whereas intracranial ependymoma is usually found in children, adults suffer mostly from spinal cord ependymoma. In comparison to other neuro-oncological tumour entities, ependymoma has been largely understudied for decades. However, the recent years resulted in unprecedented progress with regard to the understanding of the biological underpinnings and clinical features of ependymoma. Here, we review the history of ependymoma research with a focus on the development of classification models throughout the years and a discussion of the most important clinical trials that have led to the current therapeutic standard, comprising maximal safe resection and, in most cases, radiotherapy. Critically, the evidence for effective drugs and chemotherapies in ependymoma is still sparse. However, these important questions may be soon addressed with the finalisation of the currently unpublished last generation of multi-institutional trials in Europe (SIOP EP II) and Northern America (ACNS0831). Lastly, we discuss the current challenges in the field of ependymoma research and the necessary next steps towards the goal of findings cures for all types of ependymal tumours.
000309603 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000309603 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309603 650_7 $$2Other$$aEpendymal tumours
000309603 650_7 $$2Other$$aEpendymoma
000309603 650_7 $$2Other$$aMedical history
000309603 650_7 $$2Other$$aMolecular classification
000309603 7001_ $$aObrecht-Sturm, Denise$$b1
000309603 7001_ $$aWallgren, Kimberly M$$b2
000309603 7001_ $$aSchuhmann, Martin U$$b3
000309603 7001_ $$0P:(DE-HGF)0$$aTimmermann, Beate$$b4
000309603 7001_ $$aRutkowski, Stefan$$b5
000309603 7001_ $$aSchüller, Ulrich$$b6
000309603 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b7$$eLast author$$udkfz
000309603 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noag016$$gp. noag016$$pnn$$tNeuro-Oncology$$vnn$$x1522-8517$$y2026
000309603 909CO $$ooai:inrepo02.dkfz.de:309603$$pVDB
000309603 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309603 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000309603 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000309603 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000309603 9141_ $$y2026
000309603 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000309603 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000309603 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000309603 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000309603 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000309603 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x1
000309603 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000309603 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x3
000309603 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000309603 980__ $$ajournal
000309603 980__ $$aVDB
000309603 980__ $$aI:(DE-He78)B062-20160331
000309603 980__ $$aI:(DE-He78)ED01-20160331
000309603 980__ $$aI:(DE-He78)HD01-20160331
000309603 980__ $$aI:(DE-He78)HD02-20160331
000309603 980__ $$aUNRESTRICTED